Isomorphic, which formed as an Alphabet company in 2021, has a massive cash horde, but it’s tight-lipped on what drugs it ...

Isomorphic Labs, which hasn’t yet disclosed a molecule or reached the clinic, breaks the recent trend of investors putting ...

Alphabet (GOOG) unit Isomorphic Labs is conducting advanced discussions to generate more than $2B in new funding as part of a ...

In 2024, DeepMind and Isomorphic Labs released a significantly improved successor to the model. AlphaFold 3 delivers a more ...

Isomorphic Labs president Max Jaderberg said at WIRED Health in London that the startup has built a “broad and exciting pipeline of new medicines.” ...

The JavaScript innovation train is really picking up momentum lately, driven—as always—by the creativity of the JavaScript developer community. The emerging local-first SQL datastores crystalize ideas ...

Nearly two years after Google DeepMind released an updated AlphaFold3 geared at drug discovery, its biopharmaceuticals spin-off, Isomorphic Labs, announced an even more powerful ...

The unified JavaScript runtime standard is an idea whose time has come. Here’s an inside look at the movement for server-side JavaScript interoperability. The WinterCG community group was recently ...

Nearly two years after Google DeepMind released AlphaFold 3, an updated version of its system for predicting protein structure that is geared towards drug discovery, its biopharmaceuticals spin-off, ...

Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.